Drugs / OSORESNONTRINE
Trials 23 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 118 trials | ||||||
| Phase 1 | NCT04602221 | Dec 2020 → Aug 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03934203 | May → Sep 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03505151 | Apr → May 2018 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03193307 | Jun → Dec 2017 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03151499 | May → Jul 2017 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02853136 | Aug → Oct 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02635750 | Jan → Mar 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02597998 | Sep → Dec 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02438683 | May → Aug 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02392468 | Apr 2015 → Aug 2017 | Alzheimer disease, schizophrenia | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02248259 | Oct 2014 → Jan 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02222168 | Sep → Oct 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01892384 | Jun → Dec 2013 | schizophrenia | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01841112 | Apr → Jul 2013 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01611311 | May → Aug 2012 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01505894 | Jan → Jul 2012 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01493570 | Dec 2011 → Feb 2012 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01343706 | Apr → Aug 2011 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT03351244 | Dec 2017 → Mar 2021 | schizophrenia | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 2 | NCT03230097 | Sep 2017 → Mar 2021 | psychotic disorder | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 2 | NCT02337907 | Jan 2015 → Sep 2017 | Alzheimer disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02240693 | Jan 2015 → Sep 2017 | Alzheimer disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02281773 | Nov 2014 → May 2016 | schizophrenia | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OSORESNONTRINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4206492 ↗ |
| Known as | BI 409306 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01505894 ↗ |
| Known as | BI 409306 (C-13/N-15) | “On day 1, subjects were administered the Test treatment (T): a single dose of 50 milligram (mg) of BI 409306 film-coated tablet orally with 240 milliliter (mL) of water,...” NCT03505151 ↗ |
| Known as | Osoresnontrina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4206492 ↗ |
| Known as | SUB 166499 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4206492 ↗ |
| Action | Inhibit | “selective phosphodiesterase 9A (PDE9A) inhibitor” PMID 29177699 ↗ Nov 2017 |
| Modality | Small molecule | “a novel phosphodiesterase type 9 inhibitor” PMID 30755255 ↗ Feb 2019 |
| Route | Oral | “administered orally” NCT01343706 ↗ |
| Target | PDE9A | “selective phosphodiesterase 9A (PDE9A) inhibitor” PMID 29177699 ↗ Nov 2017 |